21-hydroxylase deficiency overview

Jump to navigation Jump to search

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

21-hydroxylase deficiency overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 21-hydroxylase deficiency overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 21-hydroxylase deficiency overview

CDC on 21-hydroxylase deficiency overview

21-hydroxylase deficiency overview in the news

Blogs on 21-hydroxylase deficiency overview

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Risk calculators and risk factors for 21-hydroxylase deficiency overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Ahmad Al Maradni, M.D. [3]

Overview

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OH CAH) also known as (CAH1) accounts for about 95% of diagnosed cases of congenital adrenal hyperplasia, and congenital adrenal hyperplasia in most contexts refers to 21-hydroxylase deficiency.[1] Congenital adrenal hyperplasia was first discovered by Luigi De Crecchio, an Italian anatomist. Congenital adrenal hyperplasia due to 21-hydorxylase deficiency is caused by mutations in the CYP21A2 gene. The prevalence of congenital adrenal hyperplasia due to 21-hydroxylate deficiency ranges between 6.6 to 7.6 per 100,000 individuals. The incidence of congenital adrenal hyperplasia due to 21-hydroxlase deficiency is approximately 7.1 per 100,000 births. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency usually affects individuals of the Ashkenazi Jews and Mediterranean race, and the Ashkenazi Jews to Mediterranean race ratio is approximately 1 to 3.[2] Congenital adrenal hyperplasia due to 21-hydorxylase deficiency must be differentiated from other causes of adrenal hyperplasia such as 11-β hydroxylase deficiency and 17-α hydroxylase deficiency. Symptoms of congenital adrenal hyperplasia due to 21-hydorxylase deficiency include dehydration, vomiting, and weight loss. Late symptoms include virilization and infertility. The most potent risk factor in the development of congenital adrenal hyperplasia due to 21-hydroxylase deficiency is presence of family history of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. The mainstay of therapy for congenital adrenal hyperplasia due to 21-hydorxylase deficiency is glucocorticoid replacement.

Historical Perspective

Congenital adrenal hyperplasia was first discovered by Luigi De Crecchio, an Italian anatomist.

Classification

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency may be classified into several subtypes based on severity, time of onset, and the presence of virilization.

Pathophysiology

Development of congenital adrenal hyperplasia due to 21-hydroxylase deficiency is the result of a defective P450c21 enzyme. Genes involved in the pathogenesis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency include CYP21 gene.

Causes

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is caused by mutations in the CYP21A2 gene.

Differentiating Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency from other Diseases

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency must be differentiated from 11-β hydroxylase deficiency, 17-α hydroxylase deficiency, androgen insensitivity syndrome, polycystic ovarian syndrome, and adrenal tumor.

Epidemiology and Demographics

The prevalence of congenital adrenal hyperplasia due to 21-hydroxylate deficiency ranges between 6.6 to 7.6 per 100,000 individuals. The incidence of congenital adrenal hyperplasia due to 21-hydroxlase deficiency is approximately 7.1 per 100,000 births. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency usually affects individuals of the Ashkenazi Jews and Mediterranean race, and the Ashkenazi Jews to Mediterranean race ratio is approximately 1 to 3.[2]

Risk Factors

The most potent risk factor in the development of congenital adrenal hyperplasia due to 21-hydroxylase deficiency is presence of family history of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Screening

According to the the Endocrine Society’s CGS and Clinical Affairs Core Committee, screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency by determining the serum level of 17OHP, androstenedione, and cortisol is recommended in newborns.[3][4]

Natural History, Complications and Prognosis

Common complications of 21-hydroxylase deficient congenital adrenal hyperplasia include short stature, adrenal crisis, infertility, and precocious puberty. The prognosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency is generally good with treatment.

Diagnosis

History and Symptoms

Symptoms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency include dehydration, vomiting, and weight loss. Late symptoms include virilization and infertility.

Physical Examination

Patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency usually appears underweight and dehydrated. Physical examination of patients with 21-hydroxylase deficient congenital adrenal hyperplasia is usually remarkable for hypotension and virilization.

Laboratory Findings

Laboratory findings consistent with the diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency include hyponatremia, hyperkalemia, and low cortisol level.

Ultrasound

On abdominal ultrasound, congenital adrenal hyperplasia due to 21-hydroxylase deficiency is characterized by enlarged, wrinkled surface, and cerebriform adrenal glands.[5]

CT Scan

On abdominal CT scan, congenital adrenal hyperplsia due to 21-hydroxylase deficiency is characterized by bilateral symmetric enlargement of the adrenal glands.

MRI

On abdominal MRI, congenital adrenal hyperplsia due to 21-hydroxylase deficiency is characterized by bilateral symmetric enlargement of the adrenal glands.

Other Diagnostic Studies

Immunohistochemical staining of the adrenal-gland may be used for the diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency and it shows hyperplasia, poorly defined zonation, and intermingling of the chromaffin and cortical cells.

Treatment

Medical Therapy

The mainstay of therapy for congenital adrenal hyperplasia due 21-hydroxylase deficiency is glucocorticoid replacement.

Surgery

Surgery is not the first-line treatment option for patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Surgical reconstruction of abnormal genitalia is usually reserved for severely virilized girls.

Primary Prevention

There are no primary preventive measures available for congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Secondary Prevention

Continued monitoring of hormone balance and careful readjustment of glucocorticoid dose is helpful in controlling fertility and preventing adrenal crisis in patient with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

References

  1. White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
  2. 2.0 2.1 Pang SY, Wallace MA, Hofman L, Thuline HC, Dorche C, Lyon IC; et al. (1988). "Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Pediatrics. 81 (6): 866–74. PMID 3259306.
  3. https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_21-hydroxylase_deficiency URL Accessed on 10/15/2015
  4. Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M; et al. (2009). "Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience". Pediatr Res. 66 (2): 230–5. doi:10.1203/PDR.0b013e3181aa3777. PMID 19390483.
  5. http://radiopaedia.org/articles/congenital-adrenal-hyperplasia

Template:WikiDoc Sources